Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where T. Witteveen is active.

Publication


Featured researches published by T. Witteveen.


Acta Oncologica | 2015

Establishing implantation uncertainties for focal brachytherapy with I-125 seeds for the treatment of localized prostate cancer.

D. Polders; Marcel J. Steggerda; Marcel van Herk; Kiri Nichol; T. Witteveen; L. Moonen; Jasper Nijkamp; Uulke A. van der Heide

Abstract Background. The efficacy of focal continuous low dose-rate brachytherapy (CLDR-BT) for prostate cancer requires that appropriate margins are applied to ensure robust target coverage. In this study we propose a method to establish such margins by emulating a focal treatment in patients treated with CLDR-BT to the entire gland. Material and methods. In 15 patients with localized prostate cancer, prostate volumes and dominant intra-prostatic lesions were delineated on pre-treatment magnetic resonance imaging (MRI). Delineations and MRI were registered to trans-rectal ultrasound images in the operating theater. The patients received CLDR-BT treatment to the total prostate volume. The implantation consisted of two parts: an experimental focal plan covering the dominant intra-prostatic lesion (F-GTV), followed by a plan containing additional seeds to achieve entire prostate coverage. Isodose surfaces were reconstructed using follow-up computed tomography (CT). The focal dose was emulated by reconstructing seeds from the focal plan only. The distance to agreement between planned and delivered isodose surfaces and F-GTV coverage was determined to calculate the margin required for robust treatment. Results. If patients had been treated only focally, the target volume would have been reduced from an average of 40.9 cm3 for the entire prostate to 5.8 cm3 for the focal plan. The D90 for the F-GTV in the focal plan was 195 ± 60 Gy, the V100 was 94% [range 71–100%]. The maximum distance (cd95) between the planned and delivered isodose contours was 0.48 cm. Conclusions. This study provides an estimate of 0.5 cm for the margin required for robust coverage of a focal target volume prior to actually implementing a focal treatment protocol.


Radiotherapy and Oncology | 2017

Displacement patterns of stranded I-125 seeds after permanent brachytherapy of the prostate: Dosimetry in the operating room put into perspective

Marcel J. Steggerda; Ferrie van den Boom; T. Witteveen; L. Moonen

BACKGROUND AND PURPOSE The reliability of post-implant dosimetry in the OR depends on the geometrical variability of implant and anatomy after the procedure. The purpose was to gain detailed information on seed displacement patterns in different sectors of the prostate. MATERIALS AND METHODS Of 33 patients with stranded seed implants the seed geometry and the dose distribution were compared between the situation in the OR just after the procedure, based on ultrasound images, and the situation after 1month, based on registered CT and MR images. RESULTS There was a substantial displacement of ventral seeds of 3.8±2.5mm in caudal direction (p<0.001). Of these ventral seeds cranially located seeds moved more than caudally located seeds, 4.5±2.7mm and 2.9±2.6mm, respectively (p<0.001). The D90 in the dorsal-caudal and ventral-caudal sectors increased with respectively 44±20Gy and 29±28Gy (p<0.001) and decreased with 17±31Gy in the ventral-cranial sector (p=0.008). CONCLUSIONS There were substantial changes in dose distribution 1month after the procedure, mainly due to implant and prostate shrinkage and displacement of ventral seed strands in caudal direction. When performing dynamic dosimetry or dosimetry at the end of the procedure the effect of these phenomena has to be taken into account when using stranded seeds.


Radiotherapy and Oncology | 2013

Is there a relation between the radiation dose to the different sub-segments of the lower urinary tract and urinary morbidity after brachytherapy of the prostate with I-125 seeds?

Marcel J. Steggerda; T. Witteveen; Ferrie van den Boom; L. Moonen


Radiotherapy and Oncology | 2014

Inter- and intra-fractional bladder motion during radiotherapy for bladder cancer: a comparison of full and empty bladders.

Hermine M. Dees-Ribbers; Anja Betgen; Floris J. Pos; T. Witteveen; P. Remeijer; Marcel van Herk


European Journal of Radiology | 2018

Seminal vesicle invasion on multi-parametric magnetic resonance imaging: Correlation with histopathology

Nikolaos Grivas; K. Hinnen; Jeroen de Jong; Wilma D. Heemsbergen; L. Moonen; T. Witteveen; Henk G. van der Poel; Stijn Heijmink


Radiotherapy and Oncology | 2015

OC-0134: Choline/PET CT and MRI detection of recurrences after I125 seed implant brachytherapy of prostate cancer

T. Witteveen; Wilma D. Heemsbergen; L. Moonen; Marcel J. Steggerda; S. Heijmink; U. Van der Heide


Radiotherapy and Oncology | 2015

OC-0133: How well can we predict the dose distribution from TRUS images made at the OR after I-125 brachytherapy of the prostate?

Marcel J. Steggerda; F. van den Boom; T. Witteveen; L. Moonen


Radiotherapy and Oncology | 2013

OC-0366: Establishing margins for focal brachytherapy in prostate cancer

D. Polders; Marcel J. Steggerda; M. van Herk; K. Nichol; T. Witteveen; L. Moonen; Jasper Nijkamp; U. Van der Heide


Radiotherapy and Oncology | 2013

OC-0173: Determination of a dose constraint for the minimization of urinary morbidity after brachytherapy of the prostate

Marcel J. Steggerda; T. Witteveen; F. van den Boom; L. Moonen


Radiotherapy and Oncology | 2011

88 oral PREDICTORS FOR PERSISTENT OBSTRUCTIVE URINARY SYMPTOMS REQUIRING A TURP AFTER BRACHYTHERAPY OF THE PROSTATE

Marcel J. Steggerda; T. Witteveen; H. Van Der Poel; L. Moonen

Collaboration


Dive into the T. Witteveen's collaboration.

Top Co-Authors

Avatar

L. Moonen

Netherlands Cancer Institute

View shared research outputs
Top Co-Authors

Avatar

Marcel J. Steggerda

Netherlands Cancer Institute

View shared research outputs
Top Co-Authors

Avatar

Anja Betgen

Netherlands Cancer Institute

View shared research outputs
Top Co-Authors

Avatar

D. Polders

Netherlands Cancer Institute

View shared research outputs
Top Co-Authors

Avatar

Ferrie van den Boom

Netherlands Cancer Institute

View shared research outputs
Top Co-Authors

Avatar

Floris J. Pos

Netherlands Cancer Institute

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Jasper Nijkamp

Netherlands Cancer Institute

View shared research outputs
Top Co-Authors

Avatar

M. van Herk

Netherlands Cancer Institute

View shared research outputs
Top Co-Authors

Avatar

P. Remeijer

Netherlands Cancer Institute

View shared research outputs
Researchain Logo
Decentralizing Knowledge